Is metabolic syndrome a risk factor for skin cancer? A UKBiobank Observational and two Sample Mendelian randomization Study.

IF 3.7 3区医学 Q2 ONCOLOGY Cancer Epidemiology Biomarkers & Prevention Pub Date : 2025-03-13 DOI:10.1158/1055-9965.EPI-24-1388

Emily A M Black, Claudia Allemani, Tom Dudding

{"title":"Is metabolic syndrome a risk factor for skin cancer? A UKBiobank Observational and two Sample Mendelian randomization Study.","authors":"Emily A M Black, Claudia Allemani, Tom Dudding","doi":"10.1158/1055-9965.EPI-24-1388","DOIUrl":null,"url":null,"abstract":"Background: Skin cancers (SCs) are the third most common cancer worldwide, with incidence increasing. Metabolic syndrome (MetS) is a cluster of metabolic abnormalities strongly associated with the development of cardiovascular disease. More than 1 in 5 individuals have MetS and it is linked with at least 14 different cancers. This study aimed to investigate whether MetS is a risk factor for SC.Methods: A prospective cohort study was conducted in UK Biobank. The association between MetS and SC was investigated using multivariable Poisson regression. To investigate causality, a two sample Mendelian randomization (MR) study was conducted using summary level Genome-wide association study data from UK Biobank (MetS) and FinnGen (SC).Results: 467,919 participants were included, 26.7% had MetS. Follow-up was for up to 10.8 years. MetS showed a moderately sized protective effect on BCC while the effect for SCC and MM crossed the null. Overall, MR found there was some weak evidence for increase odds of SC in those with MetS (1.07 (OR = 1.07 (95% CI: 1.01, 1.14)). Conclusions= The observational study identifies a moderately sized protective effect of MetS on BCC with MR evidence suggesting a weak causal effect is in the opposite direction.Impact: This study has found little to no effect of MetS on SC, despite links between MetS and at least 14 other cancers.","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Epidemiology Biomarkers & Prevention","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1055-9965.EPI-24-1388","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Skin cancers (SCs) are the third most common cancer worldwide, with incidence increasing. Metabolic syndrome (MetS) is a cluster of metabolic abnormalities strongly associated with the development of cardiovascular disease. More than 1 in 5 individuals have MetS and it is linked with at least 14 different cancers. This study aimed to investigate whether MetS is a risk factor for SC.

Methods: A prospective cohort study was conducted in UK Biobank. The association between MetS and SC was investigated using multivariable Poisson regression. To investigate causality, a two sample Mendelian randomization (MR) study was conducted using summary level Genome-wide association study data from UK Biobank (MetS) and FinnGen (SC).

Results: 467,919 participants were included, 26.7% had MetS. Follow-up was for up to 10.8 years. MetS showed a moderately sized protective effect on BCC while the effect for SCC and MM crossed the null. Overall, MR found there was some weak evidence for increase odds of SC in those with MetS (1.07 (OR = 1.07 (95% CI: 1.01, 1.14)). Conclusions= The observational study identifies a moderately sized protective effect of MetS on BCC with MR evidence suggesting a weak causal effect is in the opposite direction.

Impact: This study has found little to no effect of MetS on SC, despite links between MetS and at least 14 other cancers.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

背景：皮肤癌（SC）是全球第三大常见癌症，而且发病率还在不断上升。代谢综合征（MetS）是一组与心血管疾病发展密切相关的代谢异常。每 5 个人中就有超过 1 人患有代谢综合征，它与至少 14 种不同的癌症有关。本研究旨在调查 MetS 是否是 SC 的风险因素：方法：在英国生物库中进行了一项前瞻性队列研究。方法：在英国生物库中进行了一项前瞻性队列研究，采用多变量泊松回归法研究 MetS 与 SC 之间的关系。为研究因果关系，利用英国生物库（MetS）和芬兰基因（SC）的全基因组关联研究数据，进行了双样本孟德尔随机化（MR）研究：共纳入 467 919 名参与者，其中 26.7% 患有 MetS。随访时间长达 10.8 年。MetS对BCC有中等程度的保护作用，而对SCC和MM的作用则不明显。总体而言，MR发现有微弱证据表明，MetS患者患SCC的几率增加（1.07 (OR = 1.07 (95% CI: 1.01, 1.14)）。结论= 该观察性研究发现，MetS对BCC具有中等程度的保护作用，而MR证据则表明，MetS对BCC具有微弱的反向因果效应：影响：尽管 MetS 与至少 14 种其他癌症存在联系，但这项研究发现 MetS 对 SC 几乎没有影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Epidemiology Biomarkers & Prevention 医学-公共卫生、环境卫生与职业卫生

CiteScore

6.50

自引率

2.60%

发文量

538

审稿时长

1.6 months

期刊介绍： Cancer Epidemiology, Biomarkers & Prevention publishes original peer-reviewed, population-based research on cancer etiology, prevention, surveillance, and survivorship. The following topics are of special interest: descriptive, analytical, and molecular epidemiology; biomarkers including assay development, validation, and application; chemoprevention and other types of prevention research in the context of descriptive and observational studies; the role of behavioral factors in cancer etiology and prevention; survivorship studies; risk factors; implementation science and cancer care delivery; and the science of cancer health disparities. Besides welcoming manuscripts that address individual subjects in any of the relevant disciplines, CEBP editors encourage the submission of manuscripts with a transdisciplinary approach.